DON'T BUY

Their rate of growth in revenues is declining and it's not a cheap stock.

BUY

Supplies food to restaurants. It's growing faster than Sysco, less expensive, managed well and is more stable that Sysco.

DON'T BUY

Growing rapidly, but trades at 60x PE, expensive.

BUY

Not expensive valuation at 18s PE. Has a strong earnings engine to support that.  Growth is coming from the weight loss drugs. Likes them.

DON'T BUY

They fell into trouble a few years ago when they bought Hillrom, a healthcare company, which did not work. BAX took on a lot of debt and the deal was a bust. The rise of the weight-loss drugs has made a big impact on BAX's business. They have debt problems.

BUY

Pharmas have not done well. MRK trades at 8x PE. They have one large drug, Keytruda, which makes up 46% of their revenues, which is risky. The chart looks terrible. But MRK has dozens of drugs in phase 2 and 3 trials. Also, this pays a fine dividend. Now is a fine time to enter this.

TOP PICK

Has long owned them. Trades at good multiples. Shares are down a lot. Their business is structured differently from UNH, which relies on Medicare/Medicaid, but ELV runs on a fee-based system, which means less exposure to medical losses. He just added more shares today on a dip.

(Analysts’ price target is $495.15)
TOP PICK

They do military applications, like propulsion systems for the navy, radar and detection systems. 80% of business comes from the US Army, but the pressure for NATO countries to build their own defenses will be a tailwind. The US Navy has a huge submarine project that will benefit DRS. DRS has an $8.5 billion backlog.

(Analysts’ price target is $43.00)
TOP PICK

Will benefit from the strong US economy and interest rates.

(Analysts’ price target is $258.45)